Patricia Ciampa-Muske
Oncology · Sarasota, FLNPI 1922302579
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations. That places this record below the midpoint for oncology clinicians in FL, where the typical reported total is $4,167.
Across 71 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$196
- AbbVie$174
- Pfizer$144
- Gilead$120
- Bristol Myers Squibb$119
- Taiho Oncology, Inc.$116
- plus $478 from 14 others
What the payments were for
- Food & beverage$1,349100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 11 | $196 |
| AbbVie | 8 | $174 |
| Pfizer | 8 | $144 |
| Gilead | 6 | $120 |
| Bristol Myers Squibb | 6 | $119 |
| Taiho Oncology, Inc. | 7 | $116 |
| Novartis | 5 | $81 |
| Daiichi Sankyo Inc. | 3 | $70 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $57 |
| Array Biopharma Inc | 2 | $49 |
| GSK | 2 | $48 |
| Sumitomo Pharma America, Inc. | 3 | $42 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Seagen Inc. | 1 | $22 |
| Astellas Pharma US Inc | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Apellis Pharmaceuticals, Inc. | 1 | $13 |
| Amgen | 1 | $13 |
| Bayer | 1 | $13 |
| ADC Therapeutics America, Inc. | 1 | $13 |
How this compares
$1,349 in reported general payments places this provider in the 20th percentile of 24 oncology providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PomalystPomalidomide | 12 | $275,058 |
| ImbruvicaIbrutinib | 12 | $249,711 |
| JakafiRuxolitinib Phosphate | 12 | $121,867 |
| EliquisApixaban | 15 | $19,856 |
| Tamoxifen Citrate | 31 | $812 |
| Anastrozole | 19 | $333 |
| Letrozole | 11 | $260 |
| Hydroxyurea | 13 | $255 |
| Gabapentin | 19 | $198 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 11 | $150 |
| Ondansetron Hcl | 24 | $132 |
| Alprazolam | 13 | $106 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst | $196 | $275,05812 claims |
| PfizerEliquis | $144 | $19,85615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 24 oncology providers in Florida.
Other oncology in Sarasota
- Jennifer CashSarasota$294
- Beth WittmerSarasota$26
- Sara BeelerTampa$337K
- Michelle RampersadSebring$34K
- Janell VerkadenOrmond Beach$19K
- Kimberly TopeTampa$16K
- Aaron DohenySt Petersburg$14K
- Naima Vera-SommersTampa$11K
- Amber AlbaughLecanto$9K
- Natalie GessnerClearwater$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.